Funds pouring into the innovative drug sector, institutions focus on digging quality individual stocks.

In the past two months, the innovative drug sector has been experiencing fluctuations. However, from a funding perspective, a large amount of capital is still entering the market through innovative drug-themed ETFs. In the fourth quarter, the total net subscriptions of innovative drug-themed ETFs amounted to nearly 20 billion yuan. Several fund managers believe that there is still value in investing in the innovative drug sector, but it is important to focus on selecting individual stocks in the industry and positioning in high-quality companies.